Advertisement
RayBiotech
RayBiotech

Failed Drugs Expose Preclinical Blunders

Once a promising cancer treatment, the failure of PARP inhibitors in the clinic may be due to flawed preclinical studies.

By | March 30, 2012

image: Failed Drugs Expose Preclinical Blunders Wikimedia Commons, Tom Varco

WIKIMEDIA COMMONS, TOM VARCO

In January 2011, a phase III clinical trial for a highly touted new cancer therapy called iniparib, which inhibits a class of DNA-repair proteins called poly(ADP-ribose) polymerases, or PARPs, failed to prolong survival in metastatic breast cancer patients. Then in December, another leading PARP inhibitor, olaparib, performed poorly in a phase II clinical trial against ovarian cancer. Prior to large clinical trials, both drugs had shown promising, though unpublished, preclinical results, and were considered the “next big thing” in cancer therapy. But after the two failures, “clinicians were saying they didn't want to open any more clinical trials of PARP inhibitors,” Scott Kaufmann, a researcher at the Mayo Clinic in Rochester, Minnesota, told Nature.

So Kaufmann’s lab took a closer took at iniparib. Their results, published March 15 in Clinical Cancer Research, found that the drug does not actually inhibit PARP proteins, and “should not be used to guide decisions about other PARP inhibitors.”

Because the drug didn’t actually target what scientists thought it was targeting, iniparib’s failure in the clinic unfairly casts doubts on the potential of PARPs as a cancer drug target, the authors argue. And others agree. “It besmirched the entire class of compounds,” Alan Ashworth, chief executive of the Institute of Cancer Research in London, who has developed other PARP inhibitors, told Nature.

Unreliable preclinical studies, as in this case, are a problem for belt-tightening pharmaceutical companies with few resources to spare, Glenn Begley, former head of hematology and oncology at Amgen, added. “It's a distraction, and the drug-development challenge before us is already so great,” he said.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Jim Clark

Jim Clark

Posts: 1457

March 30, 2012

But olaparib also performed poorly in clinical trials, despite appearing to do the job in the preclinical paper.  And it is not clear what were the "preclinical blunders" that led to the failed clinical trials?

Avatar of:

Posts: 0

March 30, 2012

But olaparib also performed poorly in clinical trials, despite appearing to do the job in the preclinical paper.  And it is not clear what were the "preclinical blunders" that led to the failed clinical trials?

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Eppendorf
Eppendorf
Advertisement
NeuroScientistNews
NeuroScientistNews